Optimal Duration of Bismuth Quadruple Therapy for Helicobacter Pylori Eradication in Females As Compared with Males

PHASE4Enrolling by invitationINTERVENTIONAL
Enrollment

661

Participants

Timeline

Start Date

July 9, 2024

Primary Completion Date

July 31, 2032

Study Completion Date

July 31, 2032

Conditions
Helicobacter Pylori InfectionSexBismuth Quadruple Therapy
Interventions
DRUG

Drug: Bismuth Subcitrate 120 MG Oral Tablet

Bismuth Subcitrate (120 MG Oral Tablet) 1 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy

DRUG

Esomeprazole 40mg

Esomeprazole (40 mg) 1 tab per oral twice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy

DRUG

Metronidazole 250 MG

Metronidazole (250 MG) 2 tab per oral thrice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy

DRUG

Tetracycline Pill

Tetracycline (250 MG) 2 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy

Trial Locations (1)

70403

Helicobacter pylori study group, National Cheng Kung University Hospital, Tainan City

All Listed Sponsors
lead

National Cheng-Kung University Hospital

OTHER